Author

T. L. Lotan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pathology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Assay:ATAC-seq· 1 Research Focus:batch correction / integration· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. M. De Marzo· 2 shared C. E. Joshu· 2 shared J. Lu· 2 shared J. P. Maynard· 2 shared K. S. Sfanos· 2 shared M. Loda· 2 shared A. G. Sowalsky· 1 shared A. M. Carter· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. M. De Marzo

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Using Attention-based Deep Learning to Predict ERG:TMPRSS2 Fusion Status in Prostate Cancer from Whole Slide Images

M. Omar, Z. Xu, S. B. Rand, M. Mohammad, D. C. Salles, E. M. Schaeffer, B. D. Robinson, T. L. Lotan, M. Loda, L. Marchionni

This paper develops a deep learning model to predict ERG:TMPRSS2 fusion status in prostate cancer from whole slide images and identifies associated morphological features.

bioRxiv · Nov 18, 2022 · PreprintPathology

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer

M. L. Beshiri, B. J. Capaldo, R. Lake, A. T. Ku, D. Burner, C. M. Tice, C. Tran, J. Kostas, A. N. Alilin, J. Yin, S. Agarwal, S. A. Morris, F. H. Karzai, T. L. Lotan, W. L. Dahut, , K. Kelly

This study examines the origin and dynamics of cellular heterogeneity in different subtypes of castrate-resistant prostate cancer using patient-derived organoids and single-cell analyses, identifying distinct lineage plasticity patterns and therapeutic targets.

bioRxiv · Mar 24, 2022 · PreprintCancer Biology

Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays

K. H. Stopsack, S. Tyekucheva, M. Wang, T. A. Gerke, J. B. Vaselkiv, K. L. Penney, P. W. Kantoff, S. P. Finn, M. Fiorentino, M. Loda, T. L. Lotan, G. Parmigiani, L. A. Mucci

This study assesses batch effects in TMA-based cancer biomarker studies and shows mitigation methods reduce variance and alter clinical associations.

bioRxiv · Jun 29, 2021Pathology

P2X4 Purinergic Receptors as a Therapeutic Target in Aggressive Prostate Cancer

J. P. Maynard, J. Lu, I. Vidal, J. Hicks, L. Mummert, T. Ali, R. Kempski, A. M. Carter, R. Sosa, L. B. Peiffer, C. E. Joshu, T. L. Lotan, A. M. De Marzo, K. S. Sfanos

This study identifies P2X4 purinergic receptors as a driver of aggressive prostate cancer and a potential therapeutic target through in vitro and in vivo experiments.

bioRxiv · Jun 4, 2021Cancer Biology

Differential Mast Cell Phenotypes in Benign versus Cancer Tissues and Prostate Cancer Oncologic Outcomes

H. Hempel Sullivan, J. P. Maynard, C. M. Heaphy, J. Lu, A. M. De Marzo, T. L. Lotan, C. E. Joshu, K. S. Sfanos

The paper investigates differential mast cell phenotypes in benign and cancerous prostate tissues and links higher numbers of tryptase-only mast cells to worse oncologic outcomes.

bioRxiv · Jul 23, 2020Cancer Biology